Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4Genitourinary 3Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Myeloid 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Specimen Handling 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Reverse Transcriptase Polymerase Chain Reaction × Dermatologic × Clear all
NCT00667901 2009-12-11

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Rutgers, The State University of New Jersey

Phase 1 Terminated
15 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡